Clinical trials: ExtraCorporeal Life Support (ECLS)
Cardiogenic Shock, Extracorporeal Membrane Oxygenation
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation, ECLS, VA ECMO
- Trial name
- PulseSE (NCT05106491)
- Testing
- Synchronized Cardiac Support with the icor kit
- Where
- 2 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Xenios AG
Acute Decompensated Heart Failure
Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS
Extracorporeal life support (ECLS) is a circulatory cardio supplementation technique; it therefore makes it possible to compensate for a defective cardiac or cardio-respiratory function.
- Trial name
- Weanilevo (NCT04158674)
- Testing
- Levosimendan, Cernevit
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Myocardial Infarction, Shock, Cardiogenic
Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial Infarction Complicated With Cardiogenic Shock
Cardiogenic shock is currently the main cause of death after myocardial infarction and 50% of deaths occur within the first 48 hours.
- Trial name
- NCT00314847
- Testing
- Extra-Corporeal Life Support -Impella 2.5
- Where
- 13 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Caen